<p>Cadrenal Therapeutics（纳斯达克代码：CVKD）认为市场对其的解读仍然存在误读。是的，该公司确实有意保持狭窄的专注。然而，它所处的领域是医学中最被忽视的治疗领域之一。对于难以治疗的患者，抗凝治疗在几十年内没有看到实质性的创新。华法林由于缺乏创新而持续存在。直接口服抗凝药（DOACs）占据主导地位，因为替代方案没有发展。Cadrenal 正是填补这一空白，开发针对那些在使用 70 年历史药物（华法林）时最困难的患者群体的治疗方案。</p>
<p>公司的晚期资产 Tecarfarin 是一种只有在你了解当前标准有多脆弱后才会注意到的药物候选者。患有终末期肾病、房颤和严重合并症的患者无法从现有抗凝药物中获得可预测的结果。Tecarfarin 的设计旨在解决这一问题。稳定。可控。可逆。其设计反映了多年来未得到回应的临床需求。这就是 Cadrenal 开始与众不同的地方。它并不是试图赢得人气竞赛，而是试图找到更好的解决方案来弥补当前疗法的不足。</p>
<p>这种转变自八月以来已经显现。Cadrenal 提升了制造准备度。它在领导层中增加了临床深度。并且以一种立即提升公司战略地位的方式扩展了产品管线。收购 VLX-1005，这是一个针对肝素诱导性血小板减少症（&#34;HIT&#34;）的二期项目，获得了孤儿药和快速通道认证，预计将成为游戏规则的改变者。这表明 Cadrenal 打算在更大规模上参与。</p>
<p><strong>改变游戏规则的扩展</strong></p>
<p>因此，Cadrenal 不再像一个单一资产的小型公司。它表现得像一家在 400 亿美元抗凝市场内构建多重临床平台的公司。收购 Factor XIa 产品组合为急性医院环境打开了大门，在这些环境中，迫切需要更安全、更可控的抗凝治疗。当你将这一点与 tecarfarin 的慢性护理定位结合起来时，你就得到了一个在多个高价值治疗环境中具有重要影响力的公司。</p>
<p>VLX-1005 的加入进一步扩展了产品管线。HIT 是医院护理中最危险的并发症之一，而治疗选择仍然有限。拥有现有监管优势的二期资产使 Cadrenal 在临床医生渴望更好解决方案的领域中获得了立足点。这种多样化在这个规模的公司中并不常见。它改变了关于 Cadrenal 潜力的讨论。</p>
<p>估值似乎没有跟上扩展的步伐。股票仍然看起来像是公司是一个单一资产的故事，前方道路狭窄。与此同时，Cadrenal 拥有一个包含三种机制方法和多个临床催化剂的产品组合。感知与现实之间的差距通常是机会形成的地方。这种机会不会永远开放。</p>
<p><strong>弱者时期有一个到期日</strong></p>
<p>投资者开始重新发现这个故事。然而，市场似乎仍在以 Cadrenal 过去的状态来定价，而不是它正在构建的状态。解决抗凝领域实际问题的公司不会停留在小型公司领域。当它们拥有差异化资产、扩展的临床项目和可能降低监管路径风险的认证时，Cadrenal 已经将所有这些元素付诸实践。</p>
<p>这可能是任何人可以低估该公司的最后一个时期。Tecarfarin 正接近三期试验准备。VLX-1005 进入一个临床数据变得越来越重要的阶段。Factor XIa 平台赋予公司医院相关性，这是大多数小型公司从未实现的。这些并不是理论上的优势。它们今天就存在。而且更大的公司渴望将晚期资产添加到他们的投资组合中，许多药物将在本十年内到期。</p>
<p>弱者标签仍然适用，但可能不会持续太久。Cadrenal 正在为一系列里程碑做准备，预计在它们到来时会导致重新评估。市场调整的速度缓慢，但这样的管线最终会发出响亮的声音。当 Cadrenal 的数据发布时，故事可能会从被忽视转变为显而易见，而捕捉错误定价的窗口可能会迅速关闭。</p>
<p><strong>关于 Cadrenal Therapeutics, Inc.</strong></p>
<p>Cadrenal Therapeutics, Inc.正在开发差异化产品，以填补当前急性和慢性抗凝管理在稀有和高风险患者群体中的关键空白。它目前拥有三个临床阶段资产：VLX-1005，一种针对 HIT 的首创二期 12-LOX 抑制剂；tecarfarin，一种用于肾功能障碍或左心室辅助装置（LVADs）患者的慢性使用口服维生素 K 拮抗剂（VKA）；以及 frunexian，一种用于急性医院环境的肠外小分子 Factor XIa 拮抗剂。有关更多信息，请访问 https://www.cadrenal.com/ 并在 LinkedIn 上与公司联系。</p>
<p><strong>安全港</strong></p>
<p>本新闻稿中关于未来期望、计划和前景的任何声明，以及关于非历史事实事项的其他声明，可能构成 “前瞻性声明”。“预期”、“相信”、“继续”、“可能”、“估计”、“期望”、“打算”、“或许”、“计划”、“潜在”、“预测”、“项目”、“应该”、“目标”、“将”、“会” 等类似表达旨在识别前瞻性声明，尽管并非所有前瞻性声明都包含这些识别词。这些声明包括关于公司被市场误读的声明；由于缺乏创新，华法林持续存在；为最依赖 70 年历史药物的患者群体设计治疗方案；寻找更好的解决方案以弥补当前疗法的不足；收购 VLX-1005，一个针对 HIT 的 2 期项目，具有孤儿药和快速通道资格，可能成为游戏规则的改变者；表明 Cadrenal 打算在更大规模上运作；收购 Factor XIa 组合药物为急性医院环境打开大门，在这些环境中急需更安全、更可控的抗凝治疗；关于 Cadrenal 潜力的讨论；感知与现实之间的差距通常是机会形成的地方；投资者开始重新发现这个故事；这是任何人都不能低估公司的最后时刻；Tecarfarin 接近 3 期试验准备；弱者标签仍然适用，但可能不会持续太久；为一系列预期将在到来时导致重新评估的里程碑做准备，故事从被忽视转变为显而易见；以及当 Cadrenal 的数据发布时，捕捉错误定价的窗口迅速关闭。实际结果可能因各种重要因素而与这些前瞻性声明所指示的结果有实质性差异，包括继续推进新型治疗药物以治疗或预防高风险患者的血栓形成的能力；推进 VLX-1005 的临床开发以治疗 HIT 的能力；利用收购 Factor XIa 组合药物为急性医院环境打开大门的能力，在这些环境中急需更安全、更可控的抗凝治疗；按时成功完成临床试验并实现预期的结果和利益的能力；获得产品候选者商业化的监管批准或遵守持续的监管要求的能力；以及在公司截至 2024 年 12 月 31 日的 10-K 表格年度报告和公司随后向证券交易委员会提交的文件中描述的其他风险因素。本新闻稿中包含的任何前瞻性声明仅在本日期有效，除非联邦证券法要求，公司特别声明不承担更新任何前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因。</p>
<p><strong>准确性与披露声明：</strong> Hawk Point Media Group, LLC（HPM）已被 IR Agency, Inc.聘请，为 Cadrenal Therapeutics 提供新闻稿、编辑见解和数字媒体制作。此内容为赞助内容。对于 2025 年 12 月 12 日至 2025 年 12 月 16 日期间提供的服务，HPM 已通过电汇获得一万美元（USD）的报酬，用于与 Cadrenal Therapeutics 相关的内容创作和传播。此处包含的信息基于在创作时被认为准确和可靠的来源，包括公开可用的文件、公司披露和直接网站内容。此材料仅供信息参考，不应被解读为投资建议、推荐或购买或出售任何证券的要约。</p>
<p>在发布时，HPM 不拥有、购买、出售或交易所覆盖公司的证券。然而，已聘请 HPM 的个人或组织 <strong>可能</strong> 持有 Cadrenal Therapeutics 的股份，并 <strong>可能</strong> 在覆盖期间出售这些股份。这种销售可能对股价施加下行压力，并导致投资者的财务损失。</p>
<p>任何对该内容的复制、再分发或传播必须完整包含此披露。此声明是根据 1933 年证券法第 17(b) 条、联邦贸易委员会的认可指南以及其他适用法律提供的，适用于赞助通信和付费投资者内容。</p>
<p><strong>此内容的联系方式：</strong></p>
<p>info@hawkpointmedia.com</p>
<p><strong>来源：</strong> Cadrenal Therapeutics</p>
<p>查看原始新闻稿，请访问 ACCESS Newswire</p>
<p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTExNzAyMg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTExNzAyMg"/></p>

CVKD

<p>Cadrenal Therapeutics（纳斯达克代码：CVKD）正在扩大其在 400 亿美元抗凝市场的影响力，推出其晚期资产 tecarfarin，并收购 VLX-1005。该公司旨在解决当前抗凝药物的不足，特别是针对末期肾病和心房颤动患者。Cadrenal 多元化的产品线和战略收购使其具备显著增长的潜力，尽管市场尚未完全认识到其潜力。该公司正在为关键里程碑做准备，这可能会导致其股票价值的重新评估</p>

<p>Cadrenal Therapeutics (NASDAQ:CVKD) believes it continues to be misread by the market. Yes, the Company is intentionally narrowly focused. However, the lane it occupies is among the most undertreated areas in medicine. Anticoagulation for difficult-to-treat patients has not seen meaningful reinvention in decades. Warfarin persists due to a lack of innovation. DOACs dominate because alternatives have not evolved. Cadrenal is stepping into that void with therapeutics being designed for the specific patient groups who struggle most with a 70-year-old drug (warfarin).</p>
<div class="lb-trans"><p>Cadrenal Therapeutics（纳斯达克代码：CVKD）认为市场对其的解读仍然存在误读。是的，该公司确实有意保持狭窄的专注。然而，它所处的领域是医学中最被忽视的治疗领域之一。对于难以治疗的患者，抗凝治疗在几十年内没有看到实质性的创新。华法林由于缺乏创新而持续存在。直接口服抗凝药（DOACs）占据主导地位，因为替代方案没有发展。Cadrenal 正是填补这一空白，开发针对那些在使用 70 年历史药物（华法林）时最困难的患者群体的治疗方案。</p>
</div><p>Tecarfarin, the Company's late-stage asset, is the kind of drug candidate you notice only after you understand how fragile the current standard really is. Patients with end-stage kidney disease plus atrial fibrillation and advanced comorbidities do not get predictable outcomes from existing anticoagulants. Tecarfarin was engineered to solve that problem. Stable. Controlled. Reversible. The design reflects clinical demands that have gone unanswered for years. This is where Cadrenal begins to differ. It is not trying to win a popularity contest. It is trying to find a better solution to the shortcomings of current therapies.</p>
<div class="lb-trans"><p>公司的晚期资产 Tecarfarin 是一种只有在你了解当前标准有多脆弱后才会注意到的药物候选者。患有终末期肾病、房颤和严重合并症的患者无法从现有抗凝药物中获得可预测的结果。Tecarfarin 的设计旨在解决这一问题。稳定。可控。可逆。其设计反映了多年来未得到回应的临床需求。这就是 Cadrenal 开始与众不同的地方。它并不是试图赢得人气竞赛，而是试图找到更好的解决方案来弥补当前疗法的不足。</p>
</div><p>That shift has been visible since August. Cadrenal advanced manufacturing readiness. It added clinical depth inside the leadership ranks. And it expanded the pipeline in a way that instantly upgraded the company's strategic position. The acquisition of VLX-1005, a Phase 2 program with Orphan Drug and Fast Track designations for Heparin-Induced Thrombocytopenia (&#34;HIT&#34;), is expected to be a game changer. It is a signal that Cadrenal intends to play on a larger scale.</p>
<div class="lb-trans"><p>这种转变自八月以来已经显现。Cadrenal 提升了制造准备度。它在领导层中增加了临床深度。并且以一种立即提升公司战略地位的方式扩展了产品管线。收购 VLX-1005，这是一个针对肝素诱导性血小板减少症（&#34;HIT&#34;）的二期项目，获得了孤儿药和快速通道认证，预计将成为游戏规则的改变者。这表明 Cadrenal 打算在更大规模上参与。</p>
</div><p><strong>Expansion That Changes the Stakes</strong></p>
<div class="lb-trans"><p><strong>改变游戏规则的扩展</strong></p>
</div><p>With that, Cadrenal no longer behaves like a one-asset microcap. It behaves like a company constructing a multi-shot clinical platform inside the $40 billion anticoagulation market. The acquisition of a Factor XIa portfolio opened the door to acute hospital settings where safer, more controlled anticoagulation is urgently needed. When you combine that with tecarfarin's chronic-care positioning, you get a company with meaningful reach across multiple high-value treatment environments.</p>
<div class="lb-trans"><p>因此，Cadrenal 不再像一个单一资产的小型公司。它表现得像一家在 400 亿美元抗凝市场内构建多重临床平台的公司。收购 Factor XIa 产品组合为急性医院环境打开了大门，在这些环境中，迫切需要更安全、更可控的抗凝治疗。当你将这一点与 tecarfarin 的慢性护理定位结合起来时，你就得到了一个在多个高价值治疗环境中具有重要影响力的公司。</p>
</div><p>The addition of VLX-1005 further expands the pipeline. HIT is one of the most dangerous complications in hospital care, and treatment options remain limited. A Phase 2 asset with existing regulatory advantages gives Cadrenal an immediate foothold in a space where clinicians are hungry for better solutions. This kind of diversification is not common among companies of this size. It changes the conversation about Cadrenal's potential.</p>
<div class="lb-trans"><p>VLX-1005 的加入进一步扩展了产品管线。HIT 是医院护理中最危险的并发症之一，而治疗选择仍然有限。拥有现有监管优势的二期资产使 Cadrenal 在临床医生渴望更好解决方案的领域中获得了立足点。这种多样化在这个规模的公司中并不常见。它改变了关于 Cadrenal 潜力的讨论。</p>
</div><p>The valuation does not appear to have kept pace with the expansion. The stock still appears to trade as if the Company is a single-asset story with a narrow path ahead. Meanwhile, Cadrenal sits on a portfolio with three mechanistic approaches and multiple clinical catalysts. That gap between perception and reality is where opportunity usually forms. It does not stay open forever.</p>
<div class="lb-trans"><p>估值似乎没有跟上扩展的步伐。股票仍然看起来像是公司是一个单一资产的故事，前方道路狭窄。与此同时，Cadrenal 拥有一个包含三种机制方法和多个临床催化剂的产品组合。感知与现实之间的差距通常是机会形成的地方。这种机会不会永远开放。</p>
</div><p><strong>Underdog Periods Have an Expiration Date</strong></p>
<div class="lb-trans"><p><strong>弱者时期有一个到期日</strong></p>
</div><p>Investors are beginning to rediscover the story. Still, it appears the market continues to price Cadrenal for what it was, not for what it is building. Companies that solve real problems in anticoagulation do not stay in microcap territory. Not when they have differentiated assets, expanding clinical programs, and designations that potentially derisk the regulatory pathway. Cadrenal has put all those elements in motion.</p>
<div class="lb-trans"><p>投资者开始重新发现这个故事。然而，市场似乎仍在以 Cadrenal 过去的状态来定价，而不是它正在构建的状态。解决抗凝领域实际问题的公司不会停留在小型公司领域。当它们拥有差异化资产、扩展的临床项目和可能降低监管路径风险的认证时，Cadrenal 已经将所有这些元素付诸实践。</p>
</div><p>This could be the last period during which anyone can underestimate the Company. Tecarfarin is approaching Phase 3 trial readiness. VLX-1005 is entering a phase where clinical data becomes increasingly important. The Factor XIa platform gives the company hospital relevance that most microcaps never achieve. These are not theoretical advantages. They exist today. And bigger companies are hungry to add late-stage assets to their portfolios, and many of their drugs are coming off patent in this decade.</p>
<div class="lb-trans"><p>这可能是任何人可以低估该公司的最后一个时期。Tecarfarin 正接近三期试验准备。VLX-1005 进入一个临床数据变得越来越重要的阶段。Factor XIa 平台赋予公司医院相关性，这是大多数小型公司从未实现的。这些并不是理论上的优势。它们今天就存在。而且更大的公司渴望将晚期资产添加到他们的投资组合中，许多药物将在本十年内到期。</p>
</div><p>The underdog label still fits, but potentially not for long. Cadrenal is preparing for a set of milestones that are expected to lead to a reevaluation upon their arrival. The market has been slow to adjust, but pipelines like this eventually speak loudly. When Cadrenal's data hits, the story could flip from overlooked to obvious, and the window for catching the mispricing could close fast.</p>
<div class="lb-trans"><p>弱者标签仍然适用，但可能不会持续太久。Cadrenal 正在为一系列里程碑做准备，预计在它们到来时会导致重新评估。市场调整的速度缓慢，但这样的管线最终会发出响亮的声音。当 Cadrenal 的数据发布时，故事可能会从被忽视转变为显而易见，而捕捉错误定价的窗口可能会迅速关闭。</p>
</div><p><strong>About Cadrenal Therapeutics, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Cadrenal Therapeutics, Inc.</strong></p>
</div><p>Cadrenal Therapeutics, Inc. is developing differentiated products that bridge critical gaps in current acute and chronic anticoagulation management for rare and high-risk patient populations. It currently has three clinical-stage assets: VLX-1005, a first-in-class Phase 2 12-LOX Inhibitor for patients with HIT, tecarfarin, an oral vitamin K antagonist (VKA) for chronic use in patients with kidney dysfunction or left ventricular assist devices (LVADs), and frunexian, a parenteral small-molecule Factor XIa antagonist for use in acute hospital settings. For more information, visit https://www.cadrenal.com/ and connect with the Company on LinkedIn.</p>
<div class="lb-trans"><p>Cadrenal Therapeutics, Inc.正在开发差异化产品，以填补当前急性和慢性抗凝管理在稀有和高风险患者群体中的关键空白。它目前拥有三个临床阶段资产：VLX-1005，一种针对 HIT 的首创二期 12-LOX 抑制剂；tecarfarin，一种用于肾功能障碍或左心室辅助装置（LVADs）患者的慢性使用口服维生素 K 拮抗剂（VKA）；以及 frunexian，一种用于急性医院环境的肠外小分子 Factor XIa 拮抗剂。有关更多信息，请访问 https://www.cadrenal.com/ 并在 LinkedIn 上与公司联系。</p>
</div><p><strong>Safe Harbor</strong></p>
<div class="lb-trans"><p><strong>安全港</strong></p>
</div><p>Any statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute &#34;forward-looking statements.&#34; The words &#34;anticipate,&#34; &#34;believe,&#34; &#34;continue,&#34; &#34;could,&#34; &#34;estimate,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;may,&#34; &#34;plan,&#34; &#34;potentially,&#34; &#34;predict,&#34; &#34;project,&#34; &#34;should,&#34; &#34;target,&#34; &#34;will,&#34; &#34;would&#34; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include statements regarding the Company being misread by the market; Warfarin persisting due to a lack of innovation; designing therapeutics for patient groups who struggle most with a 70-year-old drug; finding a better solution to the shortcomings of current therapies; the acquisition of VLX-1005, a Phase 2 program with Orphan Drug and Fast Track designations for HIT being a game changer; signaling Cadrenal intends to play on a larger scale; the acquisition of a Factor XIa portfolio opening the door to acute hospital settings where safer, more controlled anticoagulation is urgently needed; the conversation about Cadrenal's potential; the gap between perception and reality being where opportunity usually forms; investors beginning to rediscover the story; this being the last period during which anyone can underestimate the Company; Tecarfarin approaching Phase 3 trial readiness; the underdog label still fitting, but potentially not for long; preparing for a set of milestones that are expected to lead to a reevaluation upon their arrival, and the story flipping from overlooked to obvious; and the window for catching the mispricing closing fast when Cadrenal's data hits. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability to continue to advance novel therapeutics to treat or prevent thrombosis in high-risk patients; the ability to advance the clinical development of VLX-1005 for the treatment of HIT; the ability to use the acquisition of a Factor XIa portfolio to open the door to acute hospital settings where safer, more controlled anticoagulation is urgently needed; the ability to successfully complete clinical trials on time and achieve desired results and benefits as expected; the ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements; and the other risk factors described in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and the Company's subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.</p>
<div class="lb-trans"><p>本新闻稿中关于未来期望、计划和前景的任何声明，以及关于非历史事实事项的其他声明，可能构成 “前瞻性声明”。“预期”、“相信”、“继续”、“可能”、“估计”、“期望”、“打算”、“或许”、“计划”、“潜在”、“预测”、“项目”、“应该”、“目标”、“将”、“会” 等类似表达旨在识别前瞻性声明，尽管并非所有前瞻性声明都包含这些识别词。这些声明包括关于公司被市场误读的声明；由于缺乏创新，华法林持续存在；为最依赖 70 年历史药物的患者群体设计治疗方案；寻找更好的解决方案以弥补当前疗法的不足；收购 VLX-1005，一个针对 HIT 的 2 期项目，具有孤儿药和快速通道资格，可能成为游戏规则的改变者；表明 Cadrenal 打算在更大规模上运作；收购 Factor XIa 组合药物为急性医院环境打开大门，在这些环境中急需更安全、更可控的抗凝治疗；关于 Cadrenal 潜力的讨论；感知与现实之间的差距通常是机会形成的地方；投资者开始重新发现这个故事；这是任何人都不能低估公司的最后时刻；Tecarfarin 接近 3 期试验准备；弱者标签仍然适用，但可能不会持续太久；为一系列预期将在到来时导致重新评估的里程碑做准备，故事从被忽视转变为显而易见；以及当 Cadrenal 的数据发布时，捕捉错误定价的窗口迅速关闭。实际结果可能因各种重要因素而与这些前瞻性声明所指示的结果有实质性差异，包括继续推进新型治疗药物以治疗或预防高风险患者的血栓形成的能力；推进 VLX-1005 的临床开发以治疗 HIT 的能力；利用收购 Factor XIa 组合药物为急性医院环境打开大门的能力，在这些环境中急需更安全、更可控的抗凝治疗；按时成功完成临床试验并实现预期的结果和利益的能力；获得产品候选者商业化的监管批准或遵守持续的监管要求的能力；以及在公司截至 2024 年 12 月 31 日的 10-K 表格年度报告和公司随后向证券交易委员会提交的文件中描述的其他风险因素。本新闻稿中包含的任何前瞻性声明仅在本日期有效，除非联邦证券法要求，公司特别声明不承担更新任何前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因。</p>
</div><p><strong>Accuracy &amp; Disclosure Statement:</strong> Hawk Point Media Group, LLC (HPM) has been retained by IR Agency, Inc. to provide press releases, editorial insights, and digital media production for Cadrenal Therapeutics. This content is sponsored. For services rendered from December 12, 2025 through December 16, 2025, HPM has been compensated ten thousand dollars (USD) via wire transfer for content creation and syndication related to Cadrenal Therapeutics. The information contained herein is based on sources believed to be accurate and reliable at the time of creation, including publicly available filings, company disclosures, and direct website content. This material is provided for informational purposes only and should not be interpreted as investment advice, a recommendation, or an offer to buy or sell any security.</p>
<div class="lb-trans"><p><strong>准确性与披露声明：</strong> Hawk Point Media Group, LLC（HPM）已被 IR Agency, Inc.聘请，为 Cadrenal Therapeutics 提供新闻稿、编辑见解和数字媒体制作。此内容为赞助内容。对于 2025 年 12 月 12 日至 2025 年 12 月 16 日期间提供的服务，HPM 已通过电汇获得一万美元（USD）的报酬，用于与 Cadrenal Therapeutics 相关的内容创作和传播。此处包含的信息基于在创作时被认为准确和可靠的来源，包括公开可用的文件、公司披露和直接网站内容。此材料仅供信息参考，不应被解读为投资建议、推荐或购买或出售任何证券的要约。</p>
</div><p>At the time of publication, HPM does not own, buy, sell, or trade securities of the companies covered. However, individuals or organizations that have retained HPM <strong>may</strong> hold shares of Cadrenal Therapeutics and <strong>may</strong> sell those shares during the coverage period. Such sales could place downward pressure on the stock price and result in financial loss for investors.</p>
<div class="lb-trans"><p>在发布时，HPM 不拥有、购买、出售或交易所覆盖公司的证券。然而，已聘请 HPM 的个人或组织 <strong>可能</strong> 持有 Cadrenal Therapeutics 的股份，并 <strong>可能</strong> 在覆盖期间出售这些股份。这种销售可能对股价施加下行压力，并导致投资者的财务损失。</p>
</div><p>Any reproduction, redistribution, or syndication of this content must include this disclosure in full. This statement is provided in accordance with Section 17(b) of the Securities Act of 1933, the Federal Trade Commission's Endorsement Guides, and other applicable laws governing sponsored communications and paid investor content.</p>
<div class="lb-trans"><p>任何对该内容的复制、再分发或传播必须完整包含此披露。此声明是根据 1933 年证券法第 17(b) 条、联邦贸易委员会的认可指南以及其他适用法律提供的，适用于赞助通信和付费投资者内容。</p>
</div><p><strong>Contact for this content:</strong></p>
<div class="lb-trans"><p><strong>此内容的联系方式：</strong></p>
</div><p>info@hawkpointmedia.com</p>
<div class="lb-trans"><p>info@hawkpointmedia.com</p>
</div><p><strong>SOURCE:</strong> Cadrenal Therapeutics</p>
<div class="lb-trans"><p><strong>来源：</strong> Cadrenal Therapeutics</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看原始新闻稿，请访问 ACCESS Newswire</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTExNzAyMg" alt="" original-src="https://app.accessnewswire.com/img.ashx?id=1117022"/></p>

Cadrenal 的抗凝平台正在一个 400 亿美元的市场中扩展 | CVKD 股票新闻